The intriguing fact that PAH patients have increased endostatin levels, yet simultaneously are more likely to carry a protective missense mutation leading to lower endostatin levels, highlights the need for further in-depth investigation of the causative and functional role of endostatin. This evidence concerns the gene COL18A1 and pulmonary arterial hypertension.